Defactinib
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 107 publications
Electrospun Hyaluronic Acid/Polyvinyl Alcohol Nanofibers Encapsulating Defactinib as Bioactive Dressings for Burn Wound Therapy.
Journal: ACS applied bio materials
Published: March 12, 2026
Properties of FDA-approved small molecule protein kinase inhibitors: A 2026 update.
Journal: Pharmacological research
Published: January 20, 2026
Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review.
Journal: British journal of pharmacology
Published: January 16, 2026
The combination of avutometinib and defactinib in treating recurrent low-grade serous ovarian cancer: a plain language summary of the Phase II clinical trial ENGOT-OV60/GOG-3052/RAMP 201.
Journal: Future oncology (London, England)
Published: December 12, 2025
Long lasting response to the combination of Avutometinib and Defactinib after progression on Binimetinib in a patient with recurrent low grade serous ovarian carcinoma - A case report.
Journal: Gynecologic oncology reports
Published: November 19, 2025
Unmet needs and emerging therapeutics in low-grade serous ovarian carcinoma: from chemoresistance to precision medicine.
Journal: Future oncology (London, England)
Published: November 05, 2025
FAK/SRC-JNK axis promotes ferroptosis via upregulating ACSL4 expression.
Journal: Cell death & disease
Published: October 24, 2025
Window of opportunity study measuring defactinib and avutometinib delivery in glioblastomas.
Journal: Cancer chemotherapy and pharmacology
Published: October 21, 2025
Disarming cancer resistance: FAK as a therapeutic target.
Journal: Trends in cancer
Published: October 20, 2025
Erratum: Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 13, 2025
Therapeutic advances and molecular insights in low-grade serous ovarian carcinoma.
Journal: Bulletin du cancer
Published: October 01, 2025
Last Updated: 04/28/2026